Novalis LifeSciences
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital
Stage Focus
Series A, Series B
Geographical Focus
United States, United Kingdom, Canada, Germany, Japan, Australia, Singapore, China, India, Brazil, France, Switzerland, Mexico, South Korea, Netherlands, South Africa, Russia, Belgium, Israel
Industries Focus
- Life Sciences
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Synthetic Biology
- Medical Research
- Agricultural Biotechnology
- Medical Equipment
- Genomics
- Medical Technology
- Healthcare IT
- Biopharmaceuticals
- Medical Services
- Medical Supplies
- Medical Diagnostics
- Medical Imaging
- Medical Devices and Equipment
- Medical Research and Development
- Medical Instruments
- Medical Laboratories
Investment Size:
1,000,000 to 10,000,000 USD
Investor Details Founded: 2017
Novalis LifeSciences is a globally active venture capital firm specializing in breakthrough technologies within the life sciences sector. Founded in 2017 by Marijn E. Dekkers, the firm operates with approximately $500 million in assets under management across two investment funds. Novalis LifeSciences provides direct investments through Novalis LifeSciences LLC and business advisory services through Novalis Advisory LLC. The firm's portfolio includes companies such as Cerevel Therapeutics, Quanterix, Decipher Biosciences, Celsee, and Ginkgo Bioworks, all of which have gone public or been acquired.
The firm's investment strategy focuses on highly innovative life science companies, targeting sectors such as biopharma therapeutics, life science tools, genomics, synthetic biology, molecular diagnostics, and agricultural biotechnology. Novalis LifeSciences aims to invest in 10-15 companies that are commercializing breakthrough technologies in these areas. The firm has a history of successful investments, including leading a $28 million financing for Telesis Bio in 2023 and co-leading a $116 million Series D funding round for AgBiome in 2021.
Novalis LifeSciences is led by a team of experienced operating executives from the life science industry, including founder and chairman Marijn E. Dekkers, who previously served as CEO of Bayer AG and Thermo Fisher Scientific Inc. The firm's approach combines direct investments with strategic advisory services, leveraging its team's expertise to support the growth and success of its portfolio companies. This integrated strategy has contributed to the firm's reputation as a significant player in the life sciences venture capital space.
Requirements
- Innovative life science technologies
- Strong management teams
- Scalable business models
- Potential for significant market impact
- Alignment with Novalis LifeSciences' investment focus areas
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
Portfolio Companies
- Cerevel Therapeutics
- Quanterix
- Decipher Biosciences
- Celsee
- Ginkgo Bioworks
- Telesis Bio
- AgBiome
- SkylineDx
- Biotalys
- Mercy BioAnalytics
- BlueWhale Bio
- Enko Chem
- Allurion Technologies
- Sherlock Biosciences
- Vigilant Biosciences
Mentioned In
Claim this Investor
Are you an official representative of Novalis LifeSciences?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim